ReviewMolecular and cellular endocrinology2014
STAT signaling in different breast cancer sub-types.
Review in Molecular and cellular endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Estrogen Receptors and Enzymes Involved in Estrogen Synthesis as Breast Cancer Treatment Targets.International journal of molecular sciences · 2026Review
- JAK/STAT3 axis in breast cancer: opportunities for intervention with natural phytochemical-based nanotherapeutics.Medical oncology (Northwood, London, England) · 2026Review
- Exploration of Novel Chemical Spaces to Discover JAK1 Inhibitors: An Ensemble Docking-Guided Deep Learning Approach.ACS omega · 2026Article
- NOTCH1 combined with chemotherapy synergistically inhibits triple-negative breast cancer.World journal of clinical oncology · 2025Article
- Innate immunity gene Nod2 protects mice from orthotopic breast cancer.Molecular biology reports · 2024Article
- Tissue-specific atlas of trans-models for gene regulation elucidates complex regulation patterns.BMC genomics · 2024Article
- Interplay between signal transducers and activators of transcription (STAT) proteins and cancer: involvement, therapeutic and prognostic perspective.Clinical and experimental medicine · 2023Review
- Expression pattern, prognostic value and potential microRNA silencing of FZD8 in breast cancer.Oncology letters · 2023Article
- Discovery of Highly Functionalized 5-hydroxy-2Cancers · 2022Article
- STAT-5 and STAT-6 in Breast Cancer: Potential Crosstalk With Estrogen and Progesterone Receptors Can Affect Cell Proliferation and Metastasis.Journal of clinical medicine research · 2022Article
- Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.Frontiers in molecular biosciences · 2022Review
- Olfactory receptor 5B21 drives breast cancer metastasis.iScience · 2021Article
- Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer.Cancers · 2021Review
- Article
- Sex-Gender Disparities in Cardiovascular Diseases: The Effects of Estrogen on eNOS, Lipid Profile, and NFATs During Catecholamine Stress.Frontiers in cardiovascular medicine · 2021Review
- The role of macrophages during breast cancer development and response to chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Microarray data analysis reveals gene expression changes in response to ionizing radiation in MCF7 human breast cancer cells.Hereditas · 2020Article
- The NLRP3 Inflammasome as a Critical Actor in the Inflammaging Process.Cells · 2020 · on this mapReview
- Network hub-node prioritization of gene regulation with intra-network association.BMC bioinformatics · 2020Article
- EO771, the first luminal B mammary cancer cell line from C57BL/6 mice.Cancer cell international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
This review summarizes information on expression of Signal Transducer and Activator of Transcription (STAT)s 1, 2, 3, 4, 5a/b and 6 in cancer cells from different human breast cancer sub-types. STAT proteins, especially STATs 1, 3 and 5a/b are expressed in some but not all cancers from all of the different major breast cancer sub-types. However, well-designed studies comparing expression patterns at the protein level in cancer and surrounding stromal cells are still needed to fully examine links with prognosis and therapeutic response. Moreover, it is not yet known if distinct expression patterns of STAT proteins could have dissimilar impacts in different sub-types, especially between the luminal A and B ER+ sub-types and the different TNBC sub-types. Recent data indicating that STAT 5 can be activated secondary to a therapeutic intervention and mediate resistance suggests that expression patterns should not only be examined in pre-treatment but also post-treatment samples from different sub-types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.